Based on the above results, our findings demonstrated that TPH-1 contributed to glioma development through the serotonin/L1CAM/NF-κB signaling pathway and offered possibilities for the application of TPH-1 inhibitors in glioma therapy. This evidence concerns the gene TPH1 and central nervous system cancer.